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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPERPre-Clinical Diastolic Dysfunction 407
Siu-Hin Wan, Mark W. Vogel, Horng H. Chen
Pre-clinical diastolic dysfunction (PDD) has been broadly deﬁned as left ventricular diastolic
dysfunction without the diagnosis of congestive heart failure (HF) and with normal systolic
function. PDD is an entity that remains poorly understood, yet there is a clear progression
from PDD to symptomatic HF including dyspnea, edema, and fatigue. This review focuses
on what is known about PDD, including deﬁnitions, staging, epidemiology,
pathophysiology, and the natural history of the disease.CLINICAL RESEARCH INVASIVE CARDIOLOGYNormal Coronary Angiography Rates in the VA 417
Steven M. Bradley, Thomas M. Maddox, Maggie A. Stanislawski, Colin I. O’Donnell,
Gary K. Grunwald, Thomas T. Tsai, P. Michael Ho, Eric D. Peterson, John S. Rumsfeld
The rates of normal coronary arteries with elective coronary angiography vary considerably
among U.S. community hospitals. Bradley and colleagues studied whether this variation
would be lower in an integrated healthcare system using data from 76 Veterans Affairs (VA)
hospitals. Of the nearly 25,000 patients without prior known coronary artery disease
undergoing elective angiography, 21% had no stenosis >20%. Hospital proportions of
normal coronaries varied markedly (interquartile range: 15.1% to 25.3%, range 5.5% to
48.5%). The rate of angiographically normal coronary arteries in the VA system is lower than
prior published studies in other systems. However, the observed hospital-level variation
suggests that there are opportunities to improve patient selection for diagnostic coronary
angiography.
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Nihar R. Desai, Robert P. Giugliano, Jing Zhou, Payal Kohli, Ransi Somaratne,
Elaine Hoffman, Thomas Liu, Robert Scott, Scott M. Wasserman, Marc S. Sabatine
Desai and colleagues studied the ability of AMG 145, a monoclonal antibody directed against
proprotein convertase subtilisin kexin type 9 (PCSK9), to enable subjects at high risk for
major adverse cardiovascular events to achieve low-density lipoprotein cholesterol (LDL-C)
<70 mg/dl when they have been unable to reach their target LDL-C level with high-potency
statin therapy. Subjects who were on baseline statin therapy but still had LDL >85 mg/dl
were randomly assigned to placebo or 1 of several dosages of AMG 145. Each higher dosage
of AMG 145 signiﬁcantly increased the proportion of patients achieving an LDL-C of <70
mg/dl, with 90% of subjects in both of the top dosages attaining this lipid target. There
were similar success rates for the triple lipid goal. PCSK9 inhibition with AMG 145 enables
high-risk patients to achieve established lipid goals.CARDIOMETABOLIC RISKCAC Score to Estimate Effectiveness of Polypill 434
Márcio Sommer Bittencourt, Michael J. Blaha, Ron Blankstein, Matthew Budoff, Jose D. Vargas,
Roger S. Blumenthal, Arthur S. Agatston, Khurram Nasir
Bittencourt and colleagues hypothesized that coronary artery calcium (CAC) scoring could
target those most likely to beneﬁt from the polypill strategy. Participants from MESA
(Multi-Ethnic Study of Atherosclerosis) were stratiﬁed using the eligibility criteria of
4 polypill studies (TIPS, Poly-Iran, Wald’s, and the PILL collaboration). Among MESA
participants, 40% to 60% who would have been eligible for the various polypill studies had a
CAC of 0. The estimated 5-year number needed to treat to prevent 1 cardiovascular disease
event ranged from 81 to 130 for patients with a CAC of 0, 40 to 55 for those with a CAC of
1 to 100, and 18 to 20 for those with a CAC >100. The avoidance of treatment in
individuals with a CAC of 0 could allow for signiﬁcant reductions in the population
considered for treatment with a polypill.
Editorial Comment: William Wijns, Dan Rusinaru, p. 444(continued on page A-28)
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Elisabeth Kraigher-Krainer, Amil M. Shah, Deepak K. Gupta, Angela Santos, Brian Claggett,
Burkert Pieske, Michael R. Zile, Adriaan A. Voors, Marty P. Lefkowitz, Milton Packer,
John J. V. McMurray, Scott D. Solomon, for the PARAMOUNT Investigators
Kraigher-Krainer and colleagues sought to determine the frequency and magnitude of
impaired systolic deformation in patients with heart failure with preserved ejection fraction
(HFpEF). Compared with both normal control subjects and subjects with hypertension and
diastolic dysfunction without heart failure, HFpEF patients demonstrated signiﬁcantly lower
longitudinal strain (LS) and circumferential strain (CS). Lower LS was modestly associated
with higher N-terminal pro–B-type natriuretic peptide, even after adjustment for 10 baseline
covariates. Strain imaging detects impaired systolic function despite preserved left ventricular
ejection fraction in HFpEF that may contribute to the pathophysiology of the HFpEF
syndrome.
Editorial Comment: Dalane W. Kitzman, Bharathi Upadhya, p. 457HEART VALVE DISEASELp-PLA2 and Calciﬁc Aortic Valve Disease 460Ablajan Mahmut, Marie-Chloé Boulanger, Diala El Husseini, Dominique Fournier,
Rihab Bouchareb, Jean-Pierre Després, Philippe Pibarot, Yohan Bossé, Patrick Mathieu
Mahmut and colleagues hypothesized that lipoprotein-associated phospholipase A2
(Lp-PLA2/PLA2G7) is overexpressed in calciﬁc aortic valve disease (CAVD) and promotes
the mineralization of valve interstitial cells (VICs). Explanted valves from patients with and
without CAVD were studied. Transcriptomic analyses revealed that Lp-PLA2 was increased
by 4.2-fold in mineralized aortic valves. In vitro, studies conﬁrmed that a byproduct of
Lp-PLA2 expression produced mineralization in VICs. These results demonstrate that
Lp-PLA2 is highly expressed in CAVD and plays a role in the mineralization of VICs.(continued on page A-30)
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Pia R. Kamstrup, Anne Tybjærg-Hansen, Børge G. Nordestgaard
Kamstrup and colleagues sought to determine whether elevated lipoprotein(a) levels and
corresponding LPA risk genotypes prospectively associate with an increased risk of aortic
valve stenosis (AVS). Data were compiled from 2 prospective general population studies,
following 77,680 Danish participants for up to 20 years. Elevated lipoprotein(a) levels were
associated with multivariable adjusted hazard ratios for AVS ranging from 1.2 for mild
elevations to 2.9 for levels >95th percentile, compared with levels <22nd percentile
(<4 mg/dl). Elevated lipoprotein(a) levels and corresponding genotypes correlate with an
increased risk of AVS.
Editorial Comment: Ming-Yow Hung, Joseph L. Witztum, Sotirios Tsimikas, p. 478CONGENITAL HEART DISEASEEarlier Arterial Switch Improves Outcomes and Cost 481
Brett R. Anderson, Adam J. Ciarleglio, Denise A. Hayes, Jan M. Quaegebeur, Julie A. Vincent,
Emile A. Bacha
Anderson and colleagues examined the impact of surgical timing on outcomes of infants with
dextrotransposition of the great arteries (d-TGA) who undergo neonatal arterial switch
operation (ASO). This retrospective cohort study included 140 infants at >36 weeks
gestation with d-TGA, admitted to the hospital at 5 days of age. Median age at operation
was 5 days (range: 1 to 12 days). For every day later that surgery was performed, beyond day
of life 3, the odds of major morbidity increased by 47% and costs increased by 8% after
multivariable adjustment. These results suggest that a delay of neonatal ASO beyond 3 days
is associated with increased morbidity and healthcare costs.
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